Self-stigmatization and treatment preferences: Measuring the impact of treatment labels on choices for depression medications
Product-label treatment indication can potentially lead to patient self-stigmatization as shown by patients' avoidance of treatments that are also used to treat schizophrenia. While the effect appears to be relatively small, results suggests that the issue is likely pervasive.
Authors
- Matthew T. Wallace (ORCID: https://orcid.org/0000-0002-7260-5303)
- Heidi C. Waters (ORCID: https://orcid.org/0000-0002-5671-3558)
- Juan Marcos González (ORCID: https://orcid.org/0000-0002-5386-0907)
- Michael J. Townsend (ORCID: https://orcid.org/0000-0003-0240-4562)
- Maalak Brubaker
- Reed Johnson
Institutions
- Johnson C. Smith University (US)
- Duke University (US)
- Otsuka (United States) (US)
- Clinical Research Institute (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1371/journal.pone.0309562
- Citations
- 1
- Primary Topic
- Economic and Environmental Valuation
- Type
- article
- Field-Weighted Citation Impact
- 1.13